妊娠期门诊使用 Casirivimab 和 Imdevimab 单克隆抗体治疗 COVID-19 轻症至中症。
Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019.
机构信息
Department of Clinical Medicine and Surgery, Infectious Diseases Unit University "Federico II," - Naples, Italy.
Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, - Naples, Italy.
出版信息
Am J Perinatol. 2024 Feb;41(3):365-367. doi: 10.1055/s-0042-1753488. Epub 2023 Apr 18.
OBJECTIVE
The aim of this study was to report the use casirivimab/imdevimab therapy in pregnant women with moderate coronavirus disease 2019 (COVID-19).
STUDY DESIGN
We report 12 cases of unvaccinated pregnant patients with mild-to-moderate COVID-19 treated with casirivimab/imdevimab.
RESULTS
Twelve unvaccinated pregnant patients with mild-to-moderate COVID-19 received casirivimab/imdevimab at the dose of 1200/1200 mg by intravenous infusion over 60 minutes. All women were managed outpatient. None experienced severe adverse drug reaction and none progressed to severe disease.
CONCLUSION
Casirivimab/imdevimab should be considered for outpatient treatment of unvaccinated pregnant women with mild-to-moderate COVID-19 to decrease the risk of severe disease.
KEY POINTS
· Casirivimab/imdevimab is not well studied in pregnant women.. · Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 decreases the risk of severe disease.. · Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 is well tolerated..
目的
本研究旨在报告在患有中度 2019 冠状病毒病（COVID-19）的孕妇中使用卡司瑞韦单抗/伊马韦单抗治疗的情况。
研究设计
我们报告了 12 例未接种疫苗的轻度至中度 COVID-19 孕妇接受卡司瑞韦单抗/伊马韦单抗治疗的情况。
结果
12 名未接种疫苗的轻度至中度 COVID-19 孕妇接受了卡司瑞韦单抗/伊马韦单抗治疗，剂量为 1200/1200mg，静脉输注 60 分钟。所有女性均接受门诊治疗。无严重药物不良反应发生，也无病情进展至重症。
结论
卡司瑞韦单抗/伊马韦单抗可考虑用于门诊治疗轻度至中度 COVID-19 的未接种疫苗孕妇，以降低重症风险。
重点
· 卡司瑞韦单抗/伊马韦单抗在孕妇中的研究尚不充分。· 卡司瑞韦单抗/伊马韦单抗可降低轻度至中度 COVID-19 孕妇发生重症的风险。· 卡司瑞韦单抗/伊马韦单抗在轻度至中度 COVID-19 孕妇中具有良好的耐受性。
Zotero 插件